Literature DB >> 29101187

Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction: Balancing Risks and Benefits of BP Reduction in Hypertension.

Hala Yamout1,2, George L Bakris3.   

Abstract

Entities:  

Keywords:  Kidney Function Tests; acute kidney injury; blood pressure; creatinine; hypertension; hypotension

Mesh：

Substances：

Year:  2017        PMID： 29101187      PMCID： PMC5753324          DOI： 10.2215/CJN.11811017

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  11 in total

Review 1.  Renal dysfunction complicating the treatment of hypertension.

Authors:  Biff F Palmer
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

2.  Dealing with renin-angiotensin inhibitors, don't mind serum creatinine.

Authors:  Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Am J Nephrol       Date:  2012-10-30       Impact factor: 3.754

3.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Paul K Whelton; David M Reboussin
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

4.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Authors:  Frank A Holtkamp; Dick de Zeeuw; Merlin C Thomas; Mark E Cooper; Pieter A de Graeff; Hans J L Hillege; Hans-Henrik Parving; Barry M Brenner; Shahnaz Shahinfar; Hiddo J Lambers Heerspink
Journal:  Kidney Int       Date:  2011-03-30       Impact factor: 10.612

5.  Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

Authors:  G L Bakris; M R Weir
Journal:  Arch Intern Med       Date:  2000-03-13

Review 6.  Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.

Authors:  Ivana Lazich; George L Bakris
Journal:  Semin Nephrol       Date:  2014-04-18       Impact factor: 5.299

7.  Impaired renal blood flow autoregulation in ischemic acute renal failure.

Authors:  P L Adams; F F Adams; P D Bell; L G Navar
Journal:  Kidney Int       Date:  1980-07       Impact factor: 10.612

8.  BP Reduction, Kidney Function Decline, and Cardiovascular Events in Patients without CKD.

Authors:  Rita Magriço; Miguel Bigotte Vieira; Catarina Viegas Dias; Lia Leitão; João Sérgio Neves
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-03       Impact factor: 8.237

9.  Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk.

Authors:  Elaine Ku; George Bakris; Kirsten L Johansen; Feng Lin; Mark J Sarnak; Vito M Campese; Kenneth Jamerson; Jennifer J Gassman; Miroslaw Smogorzewski; Chi-Yuan Hsu
Journal:  J Am Soc Nephrol       Date:  2017-05-04       Impact factor: 14.978

Review 10.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.

Authors:  Xinfang Xie; Emily Atkins; Jicheng Lv; Alexander Bennett; Bruce Neal; Toshiharu Ninomiya; Mark Woodward; Stephen MacMahon; Fiona Turnbull; Graham S Hillis; John Chalmers; Jonathan Mant; Abdul Salam; Kazem Rahimi; Vlado Perkovic; Anthony Rodgers
Journal:  Lancet       Date:  2015-11-07       Impact factor: 79.321
View more
  4 in total

Review 1.  Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).

Authors:  Raymond Vanholder; Steven Van Laecke; Griet Glorieux; Francis Verbeke; Esmeralda Castillo-Rodriguez; Alberto Ortiz
Journal:  Toxins (Basel)       Date:  2018-06-12       Impact factor: 4.546

2.  Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants.

Authors:  Girish N Nadkarni; Kinsuk Chauhan; Veena Rao; Joachim H Ix; Michael G Shlipak; Chirag R Parikh; Steven G Coca
Journal:  Am J Kidney Dis       Date:  2018-10-02       Impact factor: 8.860

3.  Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.

Authors:  George L Bakris; Lin Zhao; Stuart Kupfer; Attila Juhasz; Michie Hisada; Eric Lloyd; Suzanne Oparil
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-04       Impact factor: 3.738

4.  Anthropometric Development in Children: Possible Changes in Body Mass, Basal Metabolic Rate and Inflammatory Status.

Authors:  Roxana Maria Martin-Hadmaș; Ștefan Adrian Martin; Adela Romonți; Cristina Oana Mărginean
Journal:  Children (Basel)       Date:  2021-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.